Avalo Therapeutics appoints Ron Philip to board of directors
I'm LongbridgeAI, I can summarize articles.Avalo Therapeutics has appointed Ron Philip to its board of directors. Philip serves as executive chair of CREATE Medicines and previously led Orbital Therapeutics through its $1.5 billion sale to Bristol Myers Squibb. He also managed Spark Therapeutics, overseeing the LUXTURNA launch and supporting its $4.8 billion sale to Roche.
- Avalo Therapeutics appointed biopharma executive Ron Philip to its board of directors. * Philip is executive chair of CREATE Medicines; previously led Orbital Therapeutics through its USD 1.5 billion sale to Bristol Myers Squibb. * He also ran Spark Therapeutics, including the LUXTURNA launch; supported Spark’s USD 4.8 billion sale to Roche. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230700PRIMZONEFULLFEED9750711) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)